PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12684392-0	2003	Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.	Tamoxifen	86-95	tumor protein p53	Homo sapiens	48-52	
12684392-5	2003	RESULTS: In univariate analysis, both TP53 gene mutation (28% of the tumors) and a VEGF level above the median value were significantly associated with a short progression-free survival, post-relapse overall survival, and a poor rate of response to tamoxifen.	Tamoxifen	249-258	tumor protein p53	Homo sapiens	38-42	
12684392-6	2003	In Cox multivariate regression analysis including the traditional predictive factors, the addition of TP53 gene mutation and VEGF status, alone or in combination, significantly predicted a poor efficacy of tamoxifen treatment.	Tamoxifen	206-215	tumor protein p53	Homo sapiens	102-106	
12684392-9	2003	CONCLUSIONS: Combined TP53 gene mutation status and high VEGF levels of ER-positive primary breast tumors independently predict a poor course of the disease of patients with advanced breast cancer treated with tamoxifen.	Tamoxifen	210-219	tumor protein p53	Homo sapiens	22-26